Home › Companies › ERAS

Erasca, Inc.

ERAS Lead: Phase 1 7 Biotech Distilled articles ↓

Oncology Protein Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (4 active programs)

ERAS-0015

Small Molecule Target: RAS, Cyclophilin A

Solid Tumors Phase 1 oral Guangzhou Joyo Pharmatech Co., Ltd.

ERAS-4001

Small Molecule Target: KRAS

Undisclosed indication Phase 1 oral Medshine Discovery Inc.
Undisclosed indication Phase 1

ERAS-12

Protein Target: EGFR

Undisclosed indication Preclinical

Discontinued (4)

naporafenib — undisclosed · strategic decision to stop development; license termination notice sent to Novartis in March 2026
ERAS-007 — undisclosed · deprioritized; Asana License Agreement terminated effective November 8, 2025
ERAS-601 — undisclosed · deprioritized; NiKang License Agreement terminated effective October 9, 2025
ERAS-801 — Glioblastoma · deprioritized; Katmai License Agreement terminated as of April 1, 2025; rights assigned back to Katmai

Biotech Distilled coverage (7)

2026-05-12 UPDATE: Erasca (ERAS) - A $150M Mea Culpa and a Merck Wrinkle 🔒 Paid
2026-04-29 UPDATE: Erasca (ERAS) - A Buried Phase 1 Fatality and the Rapid Collapse of ERAS-0015 🔒 Paid
2026-04-28 UPDATE: Erasca (ERAS) - The Data Lands, and So Does the Lawsuit Threat 🔒 Paid
2026-04-27 UPDATE: Erasca (ERAS) - The Clock is Set for Mid-May 🔒 Paid
2026-03-14 UPDATE: Erasca (ERAS) - Burns the Boats and Goes All-In on RAS 🔒 Paid
2026-03-08 UPDATE: Erasca (ERAS) - A Free Look at a Rational Combo 🔒 Paid
2026-02-11 Erasca (ERAS): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.